GTC Biotherapeutics  and Ovation Pharmaceuticals, Inc. received approval from the FDA for ATryn (Antithrombin [Recombinant]) for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients. ATryn is the first transgenically produced therapeutic protein and the first recombinant antithrombin approved in the U.S. Also, the FDA’s Center for Veterinary Medicine approved GTC’s New Animal Drug Application, the first of its kind to regulate g...